Top

Published in:

01-01-2008 | Original Article

Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma

Authors: Enrique Lerma, Marisa Romero, Alberto Gallardo, Cristina Pons, Josefina Muñoz, Josefina Fuentes, Belen Lloveras, Lluis Catasus, Jaime Prat

Published in: Virchows Archiv | Issue 1/2008

Abstract

We studied whether Fas-receptor (Fas-R; CD95) expression, single-nucleotide polymorphisms (SNPs) in the Fas promoter region, and/or Fas-ligand (Fas-L) production could determine individual susceptibility to cervical cancer progression. The clinicopathologic features of 38 patients with cervical squamous carcinomas (22 stage I, 8 stage II, and 8 stage III+) were reviewed and related with: (a) Fas-R expression by immunohistochemistry; (b) Fas-R SNPs at -670 and -1377 locations by restriction fragment length polymorphism and DNA sequencing; and (c) Fas-L expression by immunohistochemistry. Overall and disease-free survival curves showed significant differences in relation to stage (p < 0.001). Fas-R was identified in 20 of 38 (52.6%) tumors without statistical differences in survival, stage, or Fas-L overproduction. Fas-R GG genotype was more common than expected in advanced tumors (p = 0.065). The Fas-R-1377A allele and AA genotype were unrelated with survival, stage, or Fas-R expression. Fas-L overproduction was detected in 20 of 38 (52.6%) tumors; it was more frequent in advanced-stage tumors and was inversely related to survival (p = 0.03) and decrease in host inflammatory response (p = 0.01). Fas-R expression by tumor cells seems unrelated to stage or lymphoid infiltrate. Tumor production of Fas-L may represent an attempt to destroy the host’s lymphocytic reaction.

Ahlbom A, Lichtenstein P, Malmstrom H, Feychting M, Hemminki K, Pedersen NL (1997) Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst 89:287–293PubMedCrossRef

Allen M, Lalantari M, Ylitalo N, Pettersson B, Hagmar B, Scheibenpflug L, Johansson B, Petterson U, Gyllensten U (1996) HLA DQ-DR haplotype and susceptibility to cervical carcinomaL indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 48:32–37PubMedCrossRef

Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM (1994) HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 6:157–162PubMedCrossRef

Boldrini L, Faviana P, Pistolesi F, Gisfredi S, Di Quirico D, Lucchi M, Mussi A, Angeletti CA, Baldinotti F, Fogli A, Simi P, Basolo F, Fontanini G (2001) Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene 20:6632–6637PubMedCrossRef

Butler LM, Hewett PJ, Butler WJ, Couled PA (1998) Down-regulation of fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br J Cancer 77:1454–1459PubMed

Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, Nishimura R (2000) Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 82:1682–1688PubMedCrossRef

Dybikowska A, Sliwinski W, Emerich J, Podhajska AJ (2004) Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med 14:475–478PubMed

Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS (1995) The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Med 1:464–470PubMedCrossRef

Engelmark MT, Renkema KY, Gyllensten UB (2004) No evidence of the involvement of the Fas-670 promoter polymorphism in cervical cancer in situ. Int J Cancer 112:1084–1085PubMedCrossRef

10.

Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in human autoimmune lymphoproliferative syndrome. Cell 81:935–946PubMedCrossRef

11.

Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189–1192PubMedCrossRef

12.

Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphism’s in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577–582PubMedCrossRef

13.

Inazawa J, Itoh N, Abe T, Nagata S (1992) Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 14:821–822PubMedCrossRef

14.

Jones DL, Munger K (1996) Interactions of the human papillomavirus E7 protein with cell cycle regulators. Semin Cancer Biol 7:327–337PubMedCrossRef

15.

Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM, Namkoong SE (2000) Combined analysis of germline polymorphism’s of p53, GSTM1, GSTT1, CYP1A1 and CYP2E1. Relation to the incidence rate of cervical carcinomas. Cancer 88:2082–2091PubMedCrossRef

16.

Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angstrom T, Dillner J (2000) Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 82:1332–1338PubMedCrossRef

17.

Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, Levine AM, Darragh TM, Weinberg V, Smith-McCune KK (2004) Functional attributes of mucosal immunity in cervical intraepithelial neoplasia. Cancer Res 64:6766–6774PubMedCrossRef

18.

Krammer DH (2000) CD95’s deadly mission in the immune system. Nature 407:789–795PubMedCrossRef

19.

Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, Chu TY (2005) Genetic polymorphism’s of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene–gene interaction. Gynecol Oncol 99:113–118PubMedCrossRef

20.

Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, Chang CC, Chu TY (2003) Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 103:221–225PubMedCrossRef

21.

Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY (1999) Alterations of Fas gene in transitional cell carcinomas of urinary bladder. Cancer Res 59:3068–3072PubMed

22.

Magnusson PK, Sparen P, Gyllensten UB (1999) Genetic link to cervical tumors. Nature 400:29–30PubMedCrossRef

23.

Mantovani F, Banks L (2001) The human papilloma virus E6 protein and its contribution to malignant progression. Oncogene 20:7874–7887PubMedCrossRef

24.

Matsue H, Kobayashi H, Hosokawa T, Akitaya T, Ohkawara A (1995) Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN gamma-treated cultured keratinocytes. Arch Dermatol Res 287:315–320PubMedCrossRef

25.

Milde-Langosch K, Schreiber C, Becker G, Löning T, Stegner HE (1993) Human papillomavirus a detection in cervical adenocarcinomas by polymerase chain reaction. Hum Pathol 24:590–594PubMedCrossRef

26.

Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D (1999) Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer 80:564–572PubMedCrossRef

27.

Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527PubMedCrossRef

28.

Nguyen HH, Broker TR, Chow LT, Alvarez RD, Vu HL, Andrasi J, Brewer LR, Jin G, Mestecky J (2005) Immune response to human HPV in genital tract of women with cervical cancer. Ginecol Oncol 96:452–461CrossRef

29.

Nishioka Y, Sagae S, Nishikawa A, Kudo R (2003) A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett 200:49–55PubMedCrossRef

30.

Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRef

31.

Peter ME, Krammer PH (2003) TheCD95(Apo-/Fas) DISC and beyond. Cell Death Differ 10:26–35PubMedCrossRef

32.

Pinti M, Troiano L, Nasi M, Moretti L, Monterastelli E, Mazzacani A, Mussi C, Ventura P, Olivieri F, Franceschi C, Salvioli G, Cossarizza A (2002) Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death Differ 9:431–438PubMedCrossRef

33.

Ramenghi U, Bonissoni S, Migliaretti G, DeFranco S, Bottarel F, Gambaruto C, DiFranco D, Priori R, Conti F, Dianzani I, Valesini G, Merletti F, Dianzani U (2000) Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune disease and cancer. Blood 95:3176–3182PubMed

34.

Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG (2005) Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 96:705–713PubMedCrossRef

35.

Sayama K, Yonehara S, Watanabe Y, Miki Y (1994) Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 103:330–334PubMedCrossRef

36.

Sheu BC, Hsu SM, Ho HN, Lin RH, Torng PL, Huang SC (1999) Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with progression of human cervical carcinoma. Cancer 86:1537–1543PubMedCrossRef

37.

Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y (2000) Up-regulation of Fas ligand at early stages and down regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 32:761–769PubMedCrossRef

38.

Stanczuk GA, Sibanda EN, Perrey C, Chivara M, Pravica V, Hutchinson IV, Tswana SA (2001) Cancer of the uterine cervix may be significantly associated with gene polymorphism’s coding for increased IL10 production. Int J Cancer 94:792–794PubMedCrossRef

39.

Stanczuk GA, Tswana SA, Bergstrom S, Sibanda EN (2002) Polymorphism’s in codons 10 and 25 of TGF gene in patients with invasive squamous cell carcinoma of the uterine cervix. Eur J Immunogenet 29:417–421PubMedCrossRef

40.

Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? Nat Med 2:1361–1366PubMedCrossRef

41.

Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D (2004) Polymorphism’s of death pathway genes FAS in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1030–1036PubMedCrossRef

42.

Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T, Noll M, Brocker EB, Blaser K, Akdis CA (2000) T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 106:25–35PubMedCrossRef

43.

Ueda M, Hung YC, Terai Y, Yamaguchi H, Saito J, Nunobiki O, Noda S, Ueki M (2005) Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 98:129–133PubMedCrossRef

44.

Vidal D, Matias X, Alomar A (2004) Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 29:518–525PubMedCrossRef

45.

Waggoner SE (2003) Cervical cancer. Lancet 361:2217–2225PubMedCrossRef

Title: Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma
Authors: Enrique Lerma
Marisa Romero
Alberto Gallardo
Cristina Pons
Josefina Muñoz
Josefina Fuentes
Belen Lloveras
Lluis Catasus
Jaime Prat
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 1/2008
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-007-0535-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Mature cystic teratoma of the ovary with male accessory sexual glands including seminal vesicles, prostatic tissue, and bulbo-urethral glands: a case report

Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls

Thyroid follicular carcinoma-like renal tumor: a case report with morphologic, immunophenotypic, cytogenetic, and scintigraphic studies

Pagetoid melanocytes in nevi simulant of melanoma

Brucellosis of the lung: case report and review of the literature

Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases